Novartis - Case Study

1.Novar 1.Novartis tis have played played a major major role role in the pharmac pharmaceut eutica icals ls indust industry ry over over the years. years. This company had a great vision how to grab the market and make a change that can kicks-off a  journey in the medical history h istory.. The deep sequencing of human genome and how h ow inexpensive that has become created a wealth of data that will allow new areas of discovery that have never been  possible before. ith the advent of modern technology! Novartis has made some significant changes and develop innovative new medicines in those areas. "s people age! their muscle loss become very common! and hearing loss. Technology allows to contribute in the development of new medicine and overcome those problems people face.  Novartis #$% thinks that. bioinformatics capability is very important! as is the ability to mine the data and really understand. &n addition to! &T has become a crucial part of drug discovery. &n future! meld medical! technologies will be needed to create a medical advancement.%ne bright spot for years to come is the biogeneric drugs sector! which will be one major source of revenue! and a strong engine for future growth for Novartis. 'owever! the growth of health care spending cannot continue the current rate. (o! novartis have to think other way. )ecause solid financial footing is necessary if someone*s is willing to make the wheel moving. Novartis only aim is to develop new and innovatinve medicines that can foucs and change the practi practice ce of medici medicine ne in certai certain n diseas diseasee areas! areas! so that that those those drugs drugs will will be reimburesed.These drugs remain controversial! and present no approval clear pathway in the +(" yet! due to their recent introduction to the market and some other difficult issues. They are developed at a lower cost for the drug company and will result in savings for the patient also.  Novartis has that way of pursing medical breakthrough! getting to blockbuster drugs! which is quite different than the other companies. (o ! they started that approach a decade ago what they called a pathway approach. That is used to understand the molecular pathway of particular  disease! usually in a rare disease that have a homegeneous patient population.  Novertis thought about this matter technically different from others. 'omegeneous patient  population allows to study disease and molecular pathway that leads to that disease. Then they developed a drug! which can interrupt that pathway and mechanistically expand their disease area that are impacted by the same pathway. )ut it does not mean that blockbuster will go away! 1

"n example has been given by the #$% of Novartis ,oe ,imene! about their oncology drug called "finitor! which is a mT% inhibitor. This /tor is implicated in different types of disease. (o! they had the idea to develop "finitor in renal cell cancer and then testing this "finitor in diffrent types of cancer. )reast cancer was another indication they had received approval for! which helped around thousand of patient every year. Thus! from one to another ther have just expanded it. That together made a blockbuster. 0ike others! Novartis had a plan to invest in the research and development process 234. )ut  Novastis #$% had quite different plan than others. They focus on the place! people to build their  research center. To find out world best scientist and researcher they placed their center in the developed countries. Novartis made the committment of spending 567 of their sales to 23 sector. "nd they did it perfectly. ,oe made it clear that! talent and knowledge of spending was his 1st part of success. "fterwards! he realied pathway approach would be best among those approaches and how they are going to develop and discover drugs. #onsidering demographic factors and and goverment spending behaviour made it easier for   Novartis to increase the sie of the market and improve its condition. 'owever! #hinese were spending most of the medical expenses out of their pocket. )ut the innovative drugs compelled them to spend more without an y hesitation. "part from this growth story Novartis started to think  about the less priviledge country where people do not get enough medication to survie. $ven though their economic growth is 87 to 97 per year. 0ack of infrastructure made it harder for  them to establish business and provide service on the remote area. (till! Novartis can vision a temendous growth opportunity in "frica.  Novartis committed to support ethical clinical research: new global guidelines emphasiing the  principles of ethics! governance and transparency - #linical research conducted by qualified independent investigators is an important part of drug discovery and development and can help explore unmet medical needs

2

 Novartis #$% spent most of his career in consumer product. )ut working on a diffent kind of  industry was challenging and interesting too and advised others to to play to ones strength. Though it was quite challenging for them to compete with the other established pharmaceutical. They managed it properly to get along with different kinds of diffucult situations which led them to success. The Novartis case arguably sets an important precedent for the global pharmaceutical industry andideally will help improve access to lifesaving medicines in the developing world by demanding that patient healthneeds supersede co mmercial interests.

"fter doing all these hard work!Novartis saw the face of success. "nd that*s how Novartis innovated the new market.

3

2.Recommendation

 Novartis has done a great job so far. They have created a successful company by delivering quality drugs and services to customes. /edicine industry have seen a serious change in that decade. Novartis has done a phenomenal job and brings changes to the medical industry. eing a  pharmaceutical company with advanced technology! Novartis has a lot of prospects to contribute to the industry of pharmaceutical and biomedical sciences. "t the outset! Novartis converge part of its attention into research and early development of  treatments against neglected diseases. Novartis &nstitute for Tropical 3iseases new research centre was established and is solely dedicated for researches on dengue fever! malaria and drugresistant. "part of that! diabetes being the fourth leading cause of death globally! Novartis addressed the issue by providing innovative therapies for diabetes* treatment. 'olistically! this company became a factor in improvising the world*s health by developing in these areas: pharmaceuticals! vaccines and diagnostics! (ando and consumer health. "s for Novartis which has an extensive involvement in research and development! innovation in technology would affect the business and development to the highest degree. +nderstanding this! Novartis has always been ensuring that the instrumentations as well as  pipelines of theirs are brought up to date from time to time with the maximum efficiency to enhance the productivity of the company.  Novartis &nternational "; has a well-defined framework in all the different aspects which is consent to a pharmaceutical company. ith clear and distinct mission and core competenc ies! the management has empowered the associate*s take on investing ideas and work for the company. &t is also commendable that as of now! Novartis being a /N# has complement with all the different countries* legislations in manufacturing drugs and carrying out researches.  Nevertheless! there are some recommendations that Novartis could implement in order to shape an even better pharmaceutical company with excellent progress in business and development. "t 4

the outset! Novartis should review and restructure if necessary4 the proportion of focus that has to be given to the different sectors in this company. "s of now! esearch and 3evelopment sector  has been prioritied too much. &n latter stages! there may be a possibility for Novartis to encounter high rate of discontinuation in pre-approval products. "part of that! & also recommend Novartis to focus on resources management. %ne of the implementation that they can uphold is to analyse their resources well and identify the rate of  resource wastage. "s soon as they have recognied this factor! they would be able to systematically distribute the resources for future researches. &n conclusive! & would like to quote that Novartis &nternational "; has the potential to develop to  be the world*s largest pharmaceutical company if they have employed a better marketing strategy and a comprehensive review system in all the aspect that would affect their business and development.

5